A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

Inclusion Criteria

• •To be included in the study, you must meet the following criteria:
• •Follicular NHL, grades 1 or 2 confirmed by a biopsy sample
• •18 years of age or older
• •Evidence of disease progression at time of study entry
• •Must have had at least one previous chemotherapy regimen and not more than two previous chemotherapy regimens.
• •Patients who have received previous rituximab are eligible as long as progression occurred more than six months following completion of previous rituximab therapy.
• •Measurable or evaluable disease
• •Able to perform activities of daily living without considerable assistance
• •Adequate bone marrow, kidney, and liver function
• •Signed informed consent obtained prior to initiation of any study-specific procedures or treatment.